
ERYTECH Pharma S.A. ERYP
Annual report 2022
added 12-21-2024
ERYTECH Pharma S.A. Total Liabilities 2011-2026 | ERYP
Annual Total Liabilities ERYTECH Pharma S.A.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 53.9 M | 33 M | 22.2 M | 13.8 M | 9.33 M | 5.87 M | 4.78 M | 4.36 M | 14.2 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 53.9 M | 4.36 M | 17.9 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.34 | -3.6 % | $ 357 M | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
64.9 M | $ 20.13 | -1.13 % | $ 2.81 B | ||
|
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | ||
|
Dyadic International
DYAI
|
8.71 M | $ 0.87 | - | $ 31.5 M | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
93.3 M | $ 2.57 | -3.57 % | $ 16.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Equillium
EQ
|
3.29 M | $ 2.04 | 1.24 % | $ 117 M | ||
|
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | ||
|
Fate Therapeutics
FATE
|
57.5 M | $ 1.13 | -5.04 % | $ 134 M | ||
|
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | ||
|
Forte Biosciences
FBRX
|
21.8 M | $ 26.57 | 0.49 % | $ 344 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | ||
|
Fennec Pharmaceuticals
FENC
|
35.1 M | $ 6.14 | -4.36 % | $ 175 M | ||
|
Foghorn Therapeutics
FHTX
|
307 M | $ 4.74 | -2.87 % | $ 299 M | ||
|
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | ||
|
Amicus Therapeutics
FOLD
|
676 M | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | ||
|
Fulcrum Therapeutics
FULC
|
17.3 M | $ 7.55 | -3.58 % | $ 478 K | ||
|
Galectin Therapeutics
GALT
|
146 M | $ 2.25 | -12.3 % | $ 144 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
2.76 B | $ 87.65 | -3.98 % | $ 27.2 B | ||
|
Gilead Sciences
GILD
|
39 B | $ 138.19 | -1.38 % | $ 172 B | ||
|
Coherus BioSciences
CHRS
|
197 M | $ 1.61 | -3.59 % | $ 189 M | ||
|
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 3.5 | -1.13 % | $ 236 B | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 0.54 | 4.26 % | $ 503 K | ||
|
Genmab A/S
GMAB
|
2.02 B | $ 27.01 | -2.67 % | $ 17.2 B | ||
|
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 314.44 | -4.81 % | $ 41.2 B | ||
|
Gossamer Bio
GOSS
|
295 M | $ 0.32 | -7.11 % | $ 73.1 M | ||
|
Grifols, S.A.
GRFS
|
12.8 B | $ 7.91 | -3.95 % | $ 6.83 B | ||
|
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | ||
|
GT Biopharma
GTBP
|
1.32 M | $ 0.42 | -6.49 % | $ 2.32 M | ||
|
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Halozyme Therapeutics
HALO
|
2.48 B | $ 63.51 | 0.68 % | $ 7.61 B | ||
|
Burford Capital Limited
BUR
|
1.45 B | $ 4.42 | -1.34 % | $ 727 M |